With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

GSK is expected to report profit of £4.4 billion for the first half of this year. AstraZeneca is forecast to report a ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...